Clinical Trials on Plasma in France

Total 455 results

Assistance Publique - Hôpitaux de Paris

Completed

Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia (WM2)

Waldenstrom Macroglobulinemia

France
French Innovative Leukemia Organisation

Completed

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia (RemodelWM3)

Waldenstrom Macroglobulinemia

France
University Hospital, Toulouse

Completed

IFM 99-02 Thalidomide in Myeloma

Multiple Myeloma

France
Centre Georges Francois Leclerc

Recruiting

FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM) (MIM)

Multiple Myeloma

France
CTI BioPharma
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Institut Paoli-Calmettes

Unknown

Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen (HaploMUD-RIC)

Multiple Myeloma | Non Hodgkin Lymphoma | Acute Leukemia

France
University Hospital, Montpellier
Hospices Civils de Lyon; Centre Hospitalier Universitaire de Nice; Centre Hospitalier... and other collaborators

Unknown

Place of the Hevylite Test in the Evaluation of MRD in Myeloma

Myeloma

France
Association for Training, Education, and Research...

Completed

Non-interventional Study on Salvage Auto in Relapsed Myeloma (IFM-2015-03)

Relapsed Multiple Myeloma

France
Poitiers University Hospital
Sanofi; Intergroupe Francophone du Myelome

Active, not recruiting

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

Multiple Myeloma | Myeloma | Myeloma Multiple

France
Central Hospital, Nancy, France

Terminated

Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma (IFM 01/01)

Newly Diagnosed, Multiple Myeloma

France
Central Hospital, Nancy, France

Completed

Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma (ADHOMY)

Multiple Myeloma

France
Sanofi

Completed

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Plasma Cell Myeloma

France, Germany, Italy, Spain
Centre Hospitalier Universitaire de Saint Etienne
LEO Pharma

Completed

Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer (METRO B)

Lymphoma | Multiple Myeloma

France
Centre Hospitalier Universitaire de Nice

Completed

Study of the Influence of Blue Light Emitted by Computer / Television Screens on Melasma MELABLUE Study (MELABLUE)

Melasma

France
Centre Hospitalier Universitaire de Nīmes

Terminated

MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis? (MYMO)

Myeloma

France
Poitiers University Hospital

Recruiting

Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Waldenstrom's Macroglobulinaemia Refractory

France
Nantes University Hospital

Completed

Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma

Multiple Myeloma

France
Centre Hospitalier le Mans

Completed

Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use (CARMYN)

Relapsed Multiple Myeloma

France
Centre Hospitalier Universitaire, Amiens

Withdrawn

Prevalence of Asymptomatic Thrombosis in Multiple Myeloma

Thrombosis | Multiple Myeloma

France
University Hospital, Toulouse

Not yet recruiting

ICOPE Program Feasibility in the Management of Myeloma Patients (Onco-ICOPE)

Multiple Myeloma | Frailty

France
Poitiers University Hospital
Sanofi; Celgene; Amgen; Intergroupe Francophone du Myelome

Active, not recruiting

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

France
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Institut Paoli-Calmettes

Completed

Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma (PLERIXAFOR)

Multiple Myeloma

France
Hospices Civils de Lyon

Not yet recruiting

The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma (MMSPORADGEN)

Multiple Myeloma

France
Central Hospital, Nancy, France

Completed

Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia (WAL-KU)

Waldenström Macroglobulinemia

France
Centre Hospitalier Universitaire, Amiens
Centre Henri Becquerel; University Hospital, Caen; University Hospital, Lille; Centre... and other collaborators

Recruiting

Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia (SLPRaresHvisc)

Waldenstrom Macroglobulinemia | Hyperviscosity Syndrome

France
Centre Hospitalier Universitaire, Amiens
University Hospital, Rouen; University Hospital, Caen

Recruiting

Physical Activity for Myeloma Autograft Longitudinal Study (PAMAL)

Quality of Life | Physical Activity | Multiple Myeloma

France
Janssen Research & Development, LLC

Completed

A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

Multiple Myeloma

France
Centre Hospitalier Universitaire, Amiens

Completed

Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma (MCSF-MYELOME)

Multiple Myeloma

France
Assistance Publique - Hôpitaux de Paris
INSERM UMR 1163

Not yet recruiting

Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies (GEN-HEMO-INF)

Multiple Myeloma | Waldenstrom Macroglobulinemia | Monoclonal Gammopathy of Undetermined Significance

France
Poitiers University Hospital

Completed

Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

Multiple Myeloma | Impaired Renal Function

France
Institut Paoli-Calmettes

Recruiting

Institut Paoli Calmettes Multiple Myeloma Database

Multiple Myeloma

France
Centre Hospitalier Universitaire de Nīmes
Centre Hospitalier Universitaire Dijon; Perpignan Hospital

Completed

Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment (CPS MYELOME)

Multiple Myeloma

France
University Hospital, Montpellier
Poitiers University Hospital

Unknown

Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment

Patients With Recurrent or Refractory Multiple Myeloma

France
Centre Hospitalier Universitaire, Amiens

Withdrawn

Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma (CIF-PM)

Multiple Myeloma

France
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
University Hospital, Toulouse
Sanofi; Institut National de la Santé Et de la Recherche Médicale, France; Ta...

Recruiting

Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie" (VAMOS)

Multiple Myeloma

France
Regeneron Pharmaceuticals

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4)

Multiple Myeloma

United States, France
European Society for Blood and Marrow Transplantation

Completed

Allo SCT in Amyloidosis Non-interventional Study

AL Amyloidosis

Germany, France, Switzerland
Centre Hospitalier Universitaire de Nice

Completed

Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity. (Glisodin)

Melasma

France
Centre Hospitalier Universitaire de Nice

Completed

Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma

Melasma

France
Assistance Publique - Hôpitaux de Paris

Recruiting

Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment. (MRD-CONFIRM)

Multiple Myeloma

France
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (CONFIRM)

Multiple Myeloma in Relapse

France
University Hospital, Caen
Laphal

Completed

Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies. (MAG 2002)

Multiple Myeloma de Novo Treatment

France
University Hospital, Clermont-Ferrand
Laboratoires Takeda

Unknown

Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple (SENSIB)

Multiple Myeloma | Adult | Bortezomib Regimen

France
Centre Hospitalier Henri Duffaut - Avignon
Institut de Formation en Ostéopathie du Grand Avignon

Terminated

Heart Rate Variability, Vagus Nerve and Cancer

Multiple Myeloma | Colorectal Cancer | Lung Cancer | Non Hodgkin Lymphoma

France
Nantes University Hospital

Withdrawn

Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients. (PENTI-MIDAS)

Multiple Myeloma

France
Assistance Publique - Hôpitaux de Paris

Unknown

Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI)

Multiple Myeloma | Vertebral Fracture

France
Sanofi

Terminated

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Plasma Cell Myeloma

Taiwan, United States, Czechia, France, Greece, Spain
Hospices Civils de Lyon
Janssen, LP

Completed

Multiple Myeloma Minimal Residual Disease (MMRD)

Multiple Myeloma

France

3

Subscribe